AU2015258133B2 - Bead-shaped cosmetic dosage forms - Google Patents
Bead-shaped cosmetic dosage forms Download PDFInfo
- Publication number
- AU2015258133B2 AU2015258133B2 AU2015258133A AU2015258133A AU2015258133B2 AU 2015258133 B2 AU2015258133 B2 AU 2015258133B2 AU 2015258133 A AU2015258133 A AU 2015258133A AU 2015258133 A AU2015258133 A AU 2015258133A AU 2015258133 B2 AU2015258133 B2 AU 2015258133B2
- Authority
- AU
- Australia
- Prior art keywords
- cosmetic preparation
- preparation according
- range
- previous
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 61
- 239000002552 dosage form Substances 0.000 title description 3
- 239000000126 substance Substances 0.000 claims abstract description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 19
- 239000000049 pigment Substances 0.000 claims abstract description 16
- 229920000642 polymer Polymers 0.000 claims abstract description 16
- 239000012798 spherical particle Substances 0.000 claims abstract description 12
- 239000011159 matrix material Substances 0.000 claims abstract description 10
- 229910044991 metal oxide Inorganic materials 0.000 claims abstract description 10
- 150000004706 metal oxides Chemical class 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 69
- 239000000499 gel Substances 0.000 claims description 26
- -1 Fe2O3) Chemical compound 0.000 claims description 18
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 239000000416 hydrocolloid Substances 0.000 claims description 13
- 229920001525 carrageenan Polymers 0.000 claims description 12
- 235000010418 carrageenan Nutrition 0.000 claims description 11
- 239000000679 carrageenan Substances 0.000 claims description 11
- 229940113118 carrageenan Drugs 0.000 claims description 11
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 11
- 230000009969 flowable effect Effects 0.000 claims description 10
- 229920001285 xanthan gum Polymers 0.000 claims description 10
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 10
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 9
- 235000010443 alginic acid Nutrition 0.000 claims description 9
- 229920000615 alginic acid Polymers 0.000 claims description 9
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 8
- 230000003711 photoprotective effect Effects 0.000 claims description 7
- 229920001817 Agar Polymers 0.000 claims description 5
- 235000010419 agar Nutrition 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 claims description 4
- 229940035936 ubiquinone Drugs 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims description 3
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 239000010936 titanium Substances 0.000 claims description 3
- 229910052719 titanium Inorganic materials 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003055 bisoctrizole Drugs 0.000 claims description 2
- 229910000421 cerium(III) oxide Inorganic materials 0.000 claims description 2
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000601 octocrylene Drugs 0.000 claims description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims 2
- 229910052710 silicon Inorganic materials 0.000 claims 2
- 239000010703 silicon Substances 0.000 claims 2
- 229910052726 zirconium Inorganic materials 0.000 claims 2
- 229910052684 Cerium Inorganic materials 0.000 claims 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- 229940023476 agar Drugs 0.000 claims 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 claims 1
- 229960004101 bemotrizinol Drugs 0.000 claims 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 claims 1
- 229910052748 manganese Inorganic materials 0.000 claims 1
- 239000011572 manganese Substances 0.000 claims 1
- 229960001173 oxybenzone Drugs 0.000 claims 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 claims 1
- 229960000368 sulisobenzone Drugs 0.000 claims 1
- 229940040064 ubiquinol Drugs 0.000 claims 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 claims 1
- 150000003669 ubiquinones Chemical class 0.000 abstract description 11
- 230000004224 protection Effects 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 description 48
- 210000003491 skin Anatomy 0.000 description 29
- 239000013543 active substance Substances 0.000 description 19
- 229920002125 Sokalan® Polymers 0.000 description 14
- 238000000576 coating method Methods 0.000 description 14
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 239000004904 UV filter Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- 230000005855 radiation Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 230000009759 skin aging Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000004408 titanium dioxide Substances 0.000 description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical class N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- OIQXFRANQVWXJF-QBFSEMIESA-N (2z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical class CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000206575 Chondrus crispus Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229940123457 Free radical scavenger Drugs 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229920000800 acrylic rubber Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- GLCJMPWWQKKJQZ-UHFFFAOYSA-L disodium;2-[4-(4,6-disulfonato-1h-benzimidazol-2-yl)phenyl]-1h-benzimidazole-4,6-disulfonate;hydron Chemical compound [Na+].[Na+].C1=C(S(O)(=O)=O)C=C2NC(C3=CC=C(C=C3)C3=NC4=C(C=C(C=C4N3)S(=O)(=O)O)S([O-])(=O)=O)=NC2=C1S([O-])(=O)=O GLCJMPWWQKKJQZ-UHFFFAOYSA-L 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 238000006552 photochemical reaction Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 150000004053 quinones Chemical class 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 description 2
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 2
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 206010041303 Solar dermatitis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000037338 UVA radiation Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 241000589636 Xanthomonas campestris Species 0.000 description 2
- HEAHZSUCFKFERC-LRVMPXQBSA-N [(2e)-2-[[4-[(z)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/C(C=C1)=CC=C1\C=C/1C(=O)C2(CS(O)(=O)=O)CCC\1C2(C)C HEAHZSUCFKFERC-LRVMPXQBSA-N 0.000 description 2
- ACRPXCXKILJIJN-KCDKBNATSA-N [(2r,3s,4r,5r)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl] hydrogen sulfate Chemical compound OC[C@@H](O)[C@H](OS(O)(=O)=O)[C@H](O)[C@@H](O)C=O ACRPXCXKILJIJN-KCDKBNATSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- WMWXXXSCZVGQAR-UHFFFAOYSA-N dialuminum;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3] WMWXXXSCZVGQAR-UHFFFAOYSA-N 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229960000655 ensulizole Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000004872 foam stabilizing agent Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- FKUYMLZIRPABFK-IQSNHBBHSA-N plastoquinone-9 Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=CC(=O)C(C)=C(C)C1=O FKUYMLZIRPABFK-IQSNHBBHSA-N 0.000 description 2
- 229920005862 polyol Chemical class 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical class OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- BAPRUDZDYCKSOQ-RITPCOANSA-N (2s,4r)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC(=O)N1C[C@H](O)C[C@H]1C(O)=O BAPRUDZDYCKSOQ-RITPCOANSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- GXKYGCGTJAIHDJ-UHFFFAOYSA-N 1-iodoheptan-4-yl carbamate Chemical class CCCC(OC(N)=O)CCCI GXKYGCGTJAIHDJ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 description 1
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical group OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- TVLSKGDBUQMDPR-UHFFFAOYSA-N 2,3-Dimethoxy-5-methyl-6-(3-methyl-2-buten-1-yl)-1,4-benzenediol Chemical class COC1=C(O)C(C)=C(CC=C(C)C)C(O)=C1OC TVLSKGDBUQMDPR-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- PFPQMWRASYNLMZ-LGIMBNBCSA-N 2-(3,4-dihydroxyphenyl)-3-[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 PFPQMWRASYNLMZ-LGIMBNBCSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- RRSYNAMOFATAOU-UHFFFAOYSA-N 2-cyano-3-(2-octan-3-ylphenyl)-3-phenylprop-2-enoic acid Chemical compound CCCCCC(CC)C1=CC=CC=C1C(=C(C#N)C(O)=O)C1=CC=CC=C1 RRSYNAMOFATAOU-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- NPSJHQMIVNJLNN-UHFFFAOYSA-N 2-ethylhexyl 4-nitrobenzoate Chemical compound CCCCC(CC)COC(=O)C1=CC=C([N+]([O-])=O)C=C1 NPSJHQMIVNJLNN-UHFFFAOYSA-N 0.000 description 1
- 239000004808 2-ethylhexylester Substances 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- HIPQTCQUXOFTFI-UHFFFAOYSA-N 2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)C(=O)C1=CC=CC=C1 HIPQTCQUXOFTFI-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- DWYHDSLIWMUSOO-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2N1 DWYHDSLIWMUSOO-UHFFFAOYSA-N 0.000 description 1
- FGGSPCRNKDZEKY-UHFFFAOYSA-N 3-hexoxypentane-1,2,3-triol Chemical compound CCCCCCOC(O)(CC)C(O)CO FGGSPCRNKDZEKY-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- KKJKXQYVUVWWJP-UHFFFAOYSA-N 4-[(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanylidene)methyl]benzenesulfonic acid Chemical compound CC1(C)C2CCC1(C)C(=O)C2=CC1=CC=C(S(O)(=O)=O)C=C1 KKJKXQYVUVWWJP-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- 150000005418 4-aminobenzoic acid derivatives Chemical class 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241001504639 Alcedo atthis Species 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910052582 BN Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 241001467355 Gigartina Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 229920003102 Methocel™ E4M Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- FKUYMLZIRPABFK-UHFFFAOYSA-N Plastoquinone 9 Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCC1=CC(=O)C(C)=C(C)C1=O FKUYMLZIRPABFK-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical group CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- FRGAIZLZPOROJH-BKIJVIAGSA-N [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-hydroxy-3-[2-hydroxy-3-(2-hydroxy-3-octadecanoyloxypropoxy)propoxy]propoxy]oxan-2-yl]methyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COCC(O)CO[C@H]1O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1O FRGAIZLZPOROJH-BKIJVIAGSA-N 0.000 description 1
- SZEJJURKOHIFBI-DPYQTVNSSA-N [(2r,3s,4s,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl] hydrogen sulfate Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@H](C=O)OS(O)(=O)=O SZEJJURKOHIFBI-DPYQTVNSSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 235000013804 distarch phosphate Nutrition 0.000 description 1
- 239000001245 distarch phosphate Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical group OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- HEAHZSUCFKFERC-UHFFFAOYSA-N ecamsule Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC(C=C1)=CC=C1C=C1C(=O)C2(CS(O)(=O)=O)CCC1C2(C)C HEAHZSUCFKFERC-UHFFFAOYSA-N 0.000 description 1
- 229960003747 ecamsule Drugs 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000005217 methyl ethers Chemical class 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- MJVGBKJNTFCUJM-UHFFFAOYSA-N mexenone Chemical group OC1=CC(OC)=CC=C1C(=O)C1=CC=C(C)C=C1 MJVGBKJNTFCUJM-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229960005113 oxaceprol Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N p-hydroxybenzoic acid propyl ester Natural products CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- LXTZRIBXKVRLOA-UHFFFAOYSA-N padimate a Chemical compound CCCCCOC(=O)C1=CC=C(N(C)C)C=C1 LXTZRIBXKVRLOA-UHFFFAOYSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 235000011765 phytoene Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- WKFUDLTXRQQGHB-UHFFFAOYSA-N plastoquinol-1 Chemical class CC(C)=CCC1=CC(O)=C(C)C(C)=C1O WKFUDLTXRQQGHB-UHFFFAOYSA-N 0.000 description 1
- IJBLJLREWPLEPB-IQSNHBBHSA-N plastoquinol-9 Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=CC(O)=C(C)C(C)=C1O IJBLJLREWPLEPB-IQSNHBBHSA-N 0.000 description 1
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001296 polysiloxane Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- LWBVAHQZGAKXPU-BOXHHOBZSA-M sodium;(4s)-4-amino-5-octadecoxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)[C@@H](N)CCC([O-])=O LWBVAHQZGAKXPU-BOXHHOBZSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003458 sulfonic acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- OYOGCAUNFUJOMO-UHFFFAOYSA-N trimethyl(octyl)silane Chemical compound CCCCCCCC[Si](C)(C)C OYOGCAUNFUJOMO-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008154 viscoelastic solution Substances 0.000 description 1
- 229940006076 viscoelastic substance Drugs 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
- 238000000196 viscometry Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0283—Matrix particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/28—Zirconium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Mathematical Physics (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to substantially spherical particles, whose average diameter is selected from the range of 0.1 to 10 mm, preferably 2 to 7.5 mm, and which comprise: a polymer matrix, which is substantially insoluble in water; one or more substances selected from the group of the ubiquinones and/or plastoquinones; one or more light filter substances, which is or are selected from the group of the metal oxide pigments; possibly one or more light filter substances, which is or are selected from the group of the common cosmetic light protection filter substances.
Description
(54) Bezeichnung : PERLENFORMIGE KOSMETISCHE DARREICHUNGSFORMEN (57) Abstract: The invention relates to substantially spherical particles, whose average diameter is selected from the range of 0.1 to 10 mm, preferably 2 to 7.5 mm, and which comprise: a polymer matrix, which is substantially insoluble in water; one or more substances selected from the group of the ubiquinones and/or plastoquinones; one or more light filter substances, which is or are selected from the group of the metal oxide pigments; possibly one or more light filter substances, which is or are selected from the group of the common cosmetic light protection filter substances.
(57) Zusammenfassung: Im Wesentlichen kugelformige Partikel, deren mittlerer Durchmesser gewahlt wird aus dem Bereich von
0,1 bis 10 mm, bevorzugt 2 bis 7,5 mm, und welche umfassen: - eine Polymermatrix, welche im Wesentlichen unloslich in Wasser ist, - eine oder mehrere Substanzen gewahlt aus der Gruppe der Ubichinone und/oder Plastochinone, - eine oder mehrere
Lichtfiltersubstanzen, welche gewahlt wird oder werden aus der Gruppe der Metalloxidpigmente, - gegebenenfalls eine oder mehrere
Lichtfiltersubstanzen, welche gewahlt wird oder werden aus der Gruppe der iiblichen kosmetischen Lichtschutzfiltersubstanzen.
2015258133 21 Aug 2019
Bead-shaped cosmetic dosage forms
The present invention relates to bead-shaped cosmetic dosage forms, particularly containing stabilized, oxidation- and/or UV-sensitive active agents.
The present invention relates to cosmetic and/or dermatological preparations containing active agents for the care and protection of the skin, especially sensitive and dry skin, as well as most especially, and most of all, skin which is aged or aging as the result of intrinsic and/or extrinsic factors, as well as for the support of the skin's natural lipid metabolism, and 0 the use of such active agents and combinations of such active agents in the field of cosmetic and dermatological skincare.
Cosmetic skin care should be understood primarily to mean that the natural function of the skin as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and 5 against the loss of endogenous substances (e.g. water, natural fats, electrolytes) is strengthened or restored.
If this function becomes impaired, the result can be increased resorption of toxic or allergenic substances, or attack by microorganisms, leading to toxic or allergic skin reactions.
Another aim of skincare is to compensate for the fat and water loss from the skin caused by daily washing. This is particularly important if the natural ability to regenerate is inadequate. Furthermore, skincare products should protect against environmental influences, in particular against sun and wind, and delay skin aging.
Chronological skin aging is caused, for example, by endogenous, genetically determined factors. By way of example, the epidermis and dermis, the following structural damage and functional disorders, which can also fall under the term senile xerosis, occur with increasing age:
a) dryness, roughness and formation of dryness wrinkles,
b) itching and
c) reduced refatting by sebaceous glands (e.g. after washing).
Exogenous factors, such as UV light and chemical noxae, can have a cumulative effect and,
2015258133 21 Aug 2019 for example, accelerate and/or supplement the endogenous aging processes. By way of example, in the epidermis and dermis, the following structural damage and functional disorders can occur in the skin, to a greater degree and with greater damage than in the case of chronological aging, and in particular as a result of exogenous factors:
d) visible vascular dilations (telangiectasias, cuperosis);
e) flaccidity and formation of wrinkles;
f) local hyperpigmentation, hypopigmentation and abnormal pigmentation (e.g. age spots) and
g) increased susceptibility to mechanical stress (e.g. cracking).
The present invention particularly relates to products for the care of naturally aged skin, as well as for the treatment of damage caused by photoaging, in particular the phenomena listed under a) to g).
Products for the care of aged skin are known per se. They contain, for example, retinoids (vitamin A acid and/or derivatives thereof) and/or vitamin A and/or its derivatives. Their efficacy for combatting structural damage is, however, limited. Moreover, there are considerable difficulties in product development regarding stabilizing the active agents 0 sufficiently against oxidative decomposition. The use of products containing vitamin A acid also often leads to severe erythematous skin irritations. Retinoids can therefore be employed only in low concentrations.
In particular, the present invention relates to cosmetic preparations having effective protection against harmful oxidation processes in the skin, but also for the protection of cosmetic preparations themselves and/or for the protection of the constituents of cosmetic preparations against harmful oxidation processes.
The present invention further relates to antioxidants, preferably those which are used in skin30 care cosmetics or dermatological preparations. In particular, the invention also relates to cosmetic and dermatological preparations containing such antioxidants. In a preferred embodiment, the present invention relates to cosmetic and dermatological preparations for the prophylaxis and treatment of cosmetic or dermatological changes in the skin such as skin aging - in particular skin aging caused by oxidative processes.
2015258133 21 Aug 2019
In addition, the present invention relates to active agents and preparations, containing such active agents, for the cosmetic and dermatological treatment or prophylaxis of erythematous, inflammatory, allergic or autoimmune-reactive symptoms, in particular dermatoses.
The present invention relates in a further advantageous embodiment to active agent combinations and preparations which serve the purpose of prophylaxis and treatment of photosensitive skin, in particular of photodermatoses.
The damaging effect of the ultraviolet part of solar radiation on the skin is generally known.
While rays with a wavelength of less than 290 nm (the UVC region) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema, a simple sunburn or even more-or-less severe burns.
The relatively narrow range around 308 nm is considered the maximum for the erythema activity of sunlight.
Numerous compounds are known for protection against UVB radiation, specifically derivatives of 3-benzylidenecamphor, of 4-aminobenzoic acid, of cinnamic acid, of salicylic acid, of benzophenone and also of 2-phenylbenzimidazole.
For the range between about 320 nm and about 400 nm, the so-called UVA region, it is important to have filter substances available, since rays thereof can cause reactions in cases of photosensitive skin. It has been shown that UVA radiation leads to damage of the elastic and collagenous fibers of connective tissue, which causes the skin to age prematurely, and 25 that it can be seen as a cause of numerous phototoxic and photoallergic reactions. The damaging effect of UVB radiation can be intensified by UVA radiation.
Certain derivatives of dibenzoylmethane are therefore used for protection against rays in the UVA range, wherein the photostability thereof (Int. J. Cosm. Science 10, 53 (1988)) is not 30 sufficient.
However, UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products influence the skin's metabolism.
2015258133 21 Aug 2019
Such photochemical reaction products are predominantly free-radical compounds - for example hydroxyl radicals. Undefined free-radical photoproducts which are formed in the skin itself can also result in uncontrolled secondary reactions due to their high reactivity. However, singlet oxygen, a non-radical excited state of the oxygen molecule, can also arise as a result of UV irradiation, as can short-lived epoxides and many other species. Singlet oxygen, for example, is distinguished from the triplet oxygen normally present (the freeradical ground state) by increased reactivity. However, there are also excited, reactive (radical) triplet states of the oxygen molecule.
Furthermore, UV radiation is ionizing radiation. There is therefore the risk of ionic species also arising upon UV exposure, and then being able in turn to oxidatively interrupt biochemical processes.
To prevent these reactions, additional antioxidants and/or free-radical scavengers can be incorporated into the cosmetic and/or dermatological preparations.
The use of vitamin E, a substance with known antioxidative action in sunscreen preparations, has already been suggested, although here as well the effect achieved falls far short of expectations.
The object of the invention was therefore also that of creating cosmetic, dermatological and pharmaceutical active agents and preparations, as well as photoprotective preparations, which serve the purpose of prophylaxis and treatment of photosensitive skin, in particular photodermatoses, preferably PLD.
Other names for polymorphous light dermatosis are PLD, PLE, Mallorca acne and a variety of other names, as described in the literature (for example: A. Voelckel et al, Zentralblatt Haut und Geschlechtskrankheiten (1989), 156, p. 2).
Erythematous skin symptoms also occur as accompanying symptoms in certain skin diseases or irregularities. By way of example, the typical skin rash is often red to a greater or lesser degree in the symptoms of acne.
Antioxidants are mainly used as substances which protect against the deterioration of preparations containing them. Nevertheless, it is known that undesired oxidation processes
2015258133 21 Aug 2019 can also occur in human and animal skin. Such processes play an essential role in skin aging.
The article Skin Diseases Associated with Oxidative Injury in Oxidative Stress in
Dermatology, p.323ff. (Marcel Decker Inc., New York, Basel, Hong Kong, Publisher: Jurgen Fuchs, Frankfurt, and Lester Packer, Berkeley, California) discusses oxidative skin damage and its proximate causes.
Antioxidants and/or free-radical scavengers can also be incorporated into cosmetic or dermatological preparations for the purpose of preventing such reactions.
A number of antioxidants and free radical scavengers are known. As such, the use of vitamin E, a substance with known antioxidative action in sunscreen preparations, has already been suggested in US patents 4,144,325 and 4,248,861, along with numerous other documents, although here as well the effect achieved falls far short of expectations.
Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.
The object of the present invention was therefore that of finding ways to avoid the disadvantages of the prior art. In particular, the effect of remedying the damage associated with endogenous, chronological and exogenous skin aging, and the prophylaxis, should be long-term, sustainable and without the risk of side effects.
Overcoming these shortcomings was the object of the present invention.
It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.
Furthermore, cosmetic preparations containing coenzyme Q-10, which are suitable for the treatment of skin diseases, for the prophylaxis of dystrophic and dysmetabolic conditions of the skin, and for use in chemical and physical respiratory damage or delayed respiration associated with age and wear, are known from DE 33 09 850.
2015258133 21 Aug 2019
Coenzyme Q-10 is characterized by the following structural formula
In the Japanese unexamined patent publication 58,180,410, the suitability of coenzyme Q-10 is described for cosmetics. It is believed to activate skin cell metabolism and suppress oxidation. Coenzyme Q10 accordingly has an important role in the prevention of skin damage caused by UV rays and the prevention of skin aging. In people of 20 to 40 years of age, skin roughness is improved by supplying the skin with moisture.
According to the invention, the quinones can be advantageously selected from among the group of biological quinones. Bioquinones are prenylated quinones which occur in the animal and plant kingdom, where they perform biochemical functions. Particularly preferred are ubiquinones and plastoquinones.
According to the invention, the hydroquinones can advantageously be selected from among the group of the reduced forms of the corresponding bioquinones - i.e. particularly preferably the ubiquinols and plastoquinols.
Ubiquinones represent the most widespread, and therefore best-studied, bioquinones. Ubiquinones are characterized, according to the number of isoprene units linked in the side chain, as Q-1, Q-2, Q-3, etc., or, according to the number of carbon atoms, as U-5, U-10, U15 etc. They occur preferentially with particular chain lengths for example, in some microorganisms and yeasts, where n = 6. In most mammals, including humans, Q-10 is the most common.
Ubiquinones serve the organisms as electron carriers in the respiratory chain. They are found in the mitochondria where they enable the cyclic oxidation and reduction of the substrates of the citric acid cycle.
Plastoquinones have the general structural formula:
2015258133 21 Aug 2019
for cyclic and non-cyclic electron transport, wherein they transition reversibly into the corresponding hydroquinones (plastoquinol). Plastoquinones differ in the number n of isoprene moieties and are characterized accordingly for example as PQ-9 (n = 9). Furthermore, there exist other plastoquinones with different substituents on the quinone ring.
A drawback of the prior art is that ubiquinones and plastoquinones disintegrate in an oxidative environment, as well as under UV radiation, and thus lose their effectiveness.
An object of the present invention was therefore to increase the stability of oxidation and/or UV-sensitive active agents, and to create stable preparations containing oxidation-sensitive and/or UV-sensitive active agents, wherein the effectiveness thereof is maintained over a long period.
Fluids can be distinguished with regard to their rheological properties by their flow and deformation behavior. Ideal, elastic bodies undergo elastic deformation caused by external forces, and the deformation spontaneously and completely reverses upon removal of the external force. The shape of ideal, viscous bodies is changed irreversibly by external forces.
The increasing deformation is termed flow. Most fluids are neither ideally elastic nor ideally viscous; rather, they exhibit both viscous and elastic properties and are therefore referred to as viscoelastic substances.
In the majority of viscoelastic solutions, dispersed particles or gas bubbles will always sink or rise, respectively. They have a finite structural relaxation time. This means that the networks in these systems respond to a deformation with a corresponding shear stress. However, this relaxes over a finite time to zero, such that the entire solution is again in a stable resting state without stress. This also means that these solutions have a defined zero shear viscosity, and thus achieve a constant viscosity value at low shear rates.
2015258133 21 Aug 2019
In contrast to these systems, there are also those in which dispersed particles or gas bubbles do not sediment out. It is noticeable that these systems only flow above a characteristic value. This value is called the liquid limit. Closer inspection of the rheological properties of these systems reveals that the storage modulus in the entire frequency range is independent 5 of the oscillation frequency, and always significantly greater than the loss modulus.
In contrast, the magnitude of the complex viscosity does not reach a constant value even at the smallest frequencies, but rather continues to increase.
Carbopol gels contain acrylic acid polymers which can be linear or cross-linked and which bear a high number of carboxyl groups. In dissolved form, these structures bind water. The neutralization of the carboxyl groups leads to an expansion, and hence swelling, of the polymer chains, due to the electrostatic repulsion. In this state, the Carbopol gels reach their typical rheological properties, such as the increase in the viscosity of the cosmetic preparation and/or formation of a liquid limit.
The effect of the formation of a liquid limit is thus based on the electrostatic repulsion of the carboxyl groups. Additional electrolytes shield these charges. As a result, the networks collapse, the liquid limit collapses and particles or gas bubbles can no longer be kept in 0 suspension.
The term viscosity means the property of a fluid which can resist the mutual laminar displacement of two adjacent layers (ductility, internal friction). Today, this so-called dynamic viscosity is defined as η=τ/Ο, the ratio of shear stress to the velocity gradient perpendicular 25 to the direction of flow. For Newtonian liquids, η is a material constant at a given temperature having the SI unit Pascal-second (Pa-s).
The ratio v = η/ρ of the dynamic viscosity η and the density p of the liquid is termed kinematic viscosity v, and expressed in the SI unit m2/s.
The inverse of the viscosity (cp = 1/η) is termed fluidity (cp). In ointments and the like, the use value is co-determined inter alia from the so-called ductility. The ductility of an ointment or ointment base, or the like, means its property of allowing the drawing of threads of varying lengths upon tapping; accordingly, a distinction is made between short and long ductility materials.
2015258133 21 Aug 2019
While the graphical representation of the flow behavior of Newtonian liquids at a given temperature produces a straight line, the so-called non-Newtonian liquids often produce significant deviations, depending on the respective velocity gradient D (shear rate γ) and/or the shear stress t. In these cases, the so-called apparent viscosity can be determined. Although the same do not obey the Newtonian equation, the true viscosity values can be determined from the same by graphical methods.
Falling-body viscometry is suitable only for investigating Newtonian liquids and gases. It is based on the Stokes law, according to which, for the falling of a sphere through a liquid which flows around the same, the dynamic viscosity η can be determined from:
2r2(pK -pF,)-g η =------------1 9-v wherein r = radius of the sphere, v = falling velocity, ρκ = density of the ball, pFi = density of the liquid and g = acceleration due to gravity.
Carbopol gels contain acrylic acid polymers which can be linear or cross-linked and which bear a high number of carboxyl groups. In dissolved form, these structures bind water. The neutralization of the carboxyl groups leads to an expansion, and hence swelling, of the polymer chains, due to the electrostatic repulsion. In this state, the Carbopol gels reach their typical rheological properties, such as the increase in the viscosity of the cosmetic preparation and/or formation of a liquid limit.
The effect of the formation of a liquid limit is thus based on the electrostatic repulsion of the carboxyl groups. Additional electrolytes shield these charges. As a result, the networks collapse, the liquid limit collapses and particles or gas bubbles can no longer be kept in suspension.
A further aspect of the present invention was therefore that of remedying these disadvantages.
2015258133 21 Aug 2019
In a broad aspect, the invention provides a cosmetic preparation, comprising:
an outer, flowable, gelatinous, water-based phase comprising water and one or more hydrocolloids, which has a viscosity in the range of 1,000 to 10,000 mPas at a temperature of 25 °C and a shear rate of about 10s'1, and which allows the transmission of light of the wavelength 700 nm in the range of at least 30%, and an inner, solid, particulate phase comprising substantially spherical particles with an average diameter in the range of 0.1 to 10 mm and comprising: a polymer matrix which is substantially insoluble in water and one or more light filter substances which is selected from 0 among the group of metal oxide pigments.
Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise”, “comprising”, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but 5 not limited to”.
It was surprising and unforeseeable for a person skilled in the art that - and the solution of the problems according to the invention is based on the fact that substantially spherical particles with an average diameter which is selected from the range of 0 0.1 to 10 mm, preferably 2 to 7.5 mm, and wherein the particulate phase comprises:
- a polymer matrix which is substantially insoluble in water,
- one or more substances selected from among the group of ubiquinones and/or plastoquinones,
- one or more light filter substances which is/are selected from among the group of metal oxide pigments,
- optionally one or more light filter substances which is/are selected from among the group of conventional cosmetic photoprotective filter substances, remedies the deficiencies of the prior art.
The preparations according to the invention constitute, by themselves, interesting cosmetic preparations by means of which the incorporated substances selected from the group of ubiquinones and/or plastoquinones are excellently protected against the ingress of atmospheric oxygen and harmful exposure to visible and ultraviolet light. In addition, they can
2015258133 21 Aug 2019 also in turn be incorporated into other cosmetic or dermatological preparations - in particular those which are characterized by a certain viscosity.
Particularly advantageous embodiments of the present inventions are therefore cosmetic preparations comprising:
- an outer, flowable, gelatinous, water-based phase,
- which allows the transmission of light of the wavelength 700 nm in the range of 30 to 100%, and
- which can optionally contain conventional, water-soluble or dispersible auxiliaries and/or additives,
- an inner, solid, particulate phase which
- comprises substantially spherical particles with an average diameter which is selected from the range of 0.1 to 10 mm, preferably 2 to 7.5 mm, and wherein the particulate phase comprises:
- a polymer matrix which is substantially insoluble in water,
- one or more substances selected from among the group of ubiquinones and/or plastoquinones,
- one or more light filter substances which is/are selected from among the group of metal oxide pigments,
- optionally one or more light filter substances which is/are selected from among the group of conventional cosmetic photoprotective filter substances.
Particularly advantageous embodiments of the present inventions are therefore cosmetic preparations comprising:
- an outer, flowable, gelatinous, water-based phase,
- which has a viscosity selected from the range of 1,000 to 10,000 mPas at a temperature of 25 °C and a shear rate of about 10s'1, preferably from 3000 to 9000 at a temperature of 25 °C and a shear rate of about 10s'1, and particularly preferably of 5000 to 8000 at a temperature of 25 °C and a shear rate of about
10s’1, and
- which can optionally contain conventional, water-soluble or dispersible auxiliaries and/or additives,
- an inner, solid, particulate phase which
2015258133 21 Aug 2019
- comprises substantially spherical particles with an average diameter which is selected from the range of 0.1 to 10 mm, preferably 2 to 7.5 mm, and wherein the particulate phase comprises:
- a polymer matrix which is substantially insoluble in water,
- one or more substances selected from among the group of ubiquinones and/or plastoquinones,
- one or more light filter substances which is/are selected from among the group of metal oxide pigments,
- optionally one or more light filter substances which is/are selected from among the group of conventional cosmetic photoprotective filter substances.
These preparations as well are entirely satisfactory preparations in every respect, and are not restricted to a limited choice of raw materials. Accordingly, they are particularly suitable 5 to serve as a basis for formulations having diverse applications. The preparations according to the invention exhibit very good sensory and cosmetic properties, such as extensibility on the skin or the ability to be absorbed into the skin, and are further distinguished by very good photoprotection effectiveness coupled with excellent skincare data.
When stored in light, a non-encapsulated emulsion free of light filters allows the nearly complete degradation of the active agent over time. If these active agents are present in a mixture with light filters in encapsulated form, the degradation is significantly weakened, and the active agent can be found in a high percentage even after a prolonged storage in light.
2015258133 21 Aug 2019
Table 1
Test template | Q10 [%] | |||
not irradiated | temp control * | 24 h | 48 h | |
A. ISP Captivates GL 7796 | 0.24 | 0.23 | 0.21 (87 %) | 0.16 (66 %) |
B. KONLONFREE 48 | 0.06 | 0.06 | 0.001 (1.4 %) | - |
Test template A: encapsulated emulsion with T1O2
Test template B: unencapsulated emulsion without light filter
Table 2
Test template | Q10 [%] | ||
temp control * | 24 h | 48 h | |
1. ISPCaptiv. GL 7827 | 0.145 | 0.039 (27 %) | 0.016 (11 %) |
2. ISP Captiv. GL 7834 | 0.170 | 0.010 (6 %) | 0.004 (3 %) |
3. ISP Captiv. GL 7827 in Gel 85 | 0.105 | 0.049 (47 %) | 0.035 (33 %) |
4. ISP Captiv. GL 7834 in Gel 85 | 0.076 | 0.010 (13 %) | 0.006 (7 %) |
Test template 1:
Test template 2:
Test template 3:
Test template 4:
encapsulated emulsion with high titanium dioxide fraction encapsulated emulsion with low titanium dioxide fraction encapsulated emulsion as in test template 1, high titanium dioxide fraction; beads in carrier gel encapsulated emulsion as in test template 2, with low titanium dioxide fraction; beads in carrier gel
According to the invention, advantageous preparations can be obtained by the outer, flowable, gelatinous, water-based phase containing one or more hydrocolloids, into which are incorporated the substantially spherical particles according to the invention.
Hydrocolloid is the technical abbreviation for the more correct term, hydrophilic colloid.
Hydrocolloid is the technical abbreviation for the more correct term, hydrophilic colloid. Hydrocolloids are macromolecules which have a largely linear structure and intermolecular forces of interaction which permit secondary and primary valence bonds between the
2015258133 21 Aug 2019 individual molecules, and thus the formation of a reticular structure. They increase the viscosity of the water by either binding water molecules (hydration) or else by absorbing and enveloping water into their interwoven macromolecules, while at the same time restricting the mobility of the water. Such water-soluble polymers represent a large group of chemically very different natural and synthetic polymers whose common feature is their solubility in water or aqueous media. The prerequisite for this is that these polymers have a sufficient number of hydrophilic groups for solubility in water, and are not too greatly crosslinked. The hydrophilic groups can be nonionic, anionic or cationic in nature, for example as follows:
+
—nh2 | —COOH | —COO | M+ | —nr2 |
—NH—R | 0 || | —so3- | M + | (CH2)n |
—OH | —NH—C—NH2 | -pof | m2+ | so3‘ |
—SH | NH | —nh3 | X' | + |
II | + | —nr2 | ||
—ο- | — NH—C—NH2 | —nr2h | X' | I |
ι | + | (CH2)n | ||
— N— | —HN. ,N. .NH2 | —nr3 | X- | I |
Y Y | + —pr3 | x' | COO' | |
N^N | ||||
NHo | O' |
+/ —CH=N
O
The group of cosmetically and dermatologically relevant hydrocolloids can be divided as follows into:
organic, natural compounds, such as, for example, agar-agar, carrageenan, tragacanth, gum arabic, alginates, pectins, polyoses, guar gum, carob bean gum, starches, dextrins, gelatins, casein;
organic, modified natural substances, such as, for example, carboxymethylcellulose and other cellulose ethers, hydroxyethyl and hydroxypropyl cellulose and the like;
organic, completely synthetic compounds such as, for example, polyacrylic and polymethacrylic compounds, vinyl polymers, polycarboxylic acids, polyethers, polyimines, polyamides;
inorganic compounds, such as, for example, polysilicic acids, clay minerals such as montmorillonite, zeolites, silicas.
According to the invention, preferred hydrocolloids are, for example, methylcelluloses, which is the name for the methyl ethers of cellulose. They are characterized by the following structural formula:
2015258133 21 Aug 2019
ROCH2
OR
Structural formula I in which R can represent a hydrogen or a methyl group.
Particularly advantageous for the purposes of the present invention are the mixed cellulose ethers, likewise generally referred to as methylcelluloses, which in addition to a predominant 0 content of methyl groups also contain 2-hydroxyethyl, 2-hydroxypropyl or 2-hydroxybutyl groups. (Hydroxypropyl)methylcelluloses are particularly preferred - by way of example those available under the trade name Methocel E4M from the Dow Chemical Comp.
According to the invention, sodium carboxymethylcellulose is also advantageous, along with 5 the sodium salt of the glycolic ether of the cellulose, for which R in structural formula I is hydrogen and/or CH2COONa. Particular preference is given to sodium carboxymethylcellulose, available under the trade name Natrosol Plus 330 CS from Aquaion, and also known as cellulose gum.
Particularly preferred according to the present invention is xanthan (CAS-No.1 1 138-66-2), also called xanthan gum, which is an anionic heteropolysaccharide which is generally formed by fermentation from corn sugar and is isolated as the potassium salt. It is produced by Xanthomonas campestris and several other species under aerobic conditions, with a molecular weight of 2x106 to 24x106. Xanthan is formed from a chain with β-1,4-bonded glucose (cellulose) with side chains. The structure of the subgroups consists of glucose, mannose, glucuronic acid, acetate and pyruvate. Xanthan is the name for the first microbial, anionic heteropolysaccharide. It is produced by Xanthomonas campestris and some other species under aerobic conditions, with a molecular weight of 2x106 to 15x106. Xanthan is formed from a chain with β-1,4-bonded glucose (cellulose) with side chains. The structure of the subgroups consists of glucose, mannose, glucuronic acid, acetate and pyruvate. The number of pyruvate units determines the viscosity of the xanthan. Xanthan is produced in
2015258133 21 Aug 2019 two-day batch cultures with a yield of 70-90% based on carbohydrate used. Yields of 25-30 g/L are achieved. The batch is worked up by killing the culture by precipitation with, for example, 2-propanol. Xanthan is subsequently dried and ground.
A particularly advantageous gel former for the purposes of the present invention is, furthermore, carrageenan, a gel-forming extract similar in structure to agar, from red algaes present in the North Atlantic and classified among theflorideaes (Chondrus crispus and Gigartina stellata).
Often, the name carrageen is used for the dried algae product and carrageenan for the extract thereof. The carrageenan precipitated from the hot water extract of the algae is a colorless to sand-colored powder with a molecular weight range of 100,000 to 800,000 and a sulfate content of about 25%. Carrageenan, which is very readily soluble in warm water, forms a thixotropic gel upon cooling, even if the water content is 95-98%. The strength of the gel is the result of the double helix structure of the carrageenan. There are three main components of carrageenan: the gel-forming κ fraction consists of D-galactose-4-sulfate and 3,6-anhydro-a-D-galactose, which has alternating glycoside bonds in the 1,3 and Impositions (agar, in contrast, contains 3,6-anhydro-a-L-galactose). The non-gelling λ fraction is composed of 1,3-glycosidically linked D-galactose-2-sulfate and 1,4-linked D-galactose-2,60 disulfate moieties, and is highly soluble in cold water. The ι-carrageenan from D-galactose-4sulfate at the 1,3 position and 3,6-anhydro-a-D-galactose-2-sulfate at the 1,4 position is both water soluble and gel-forming. Further carrageen types are likewise referred to with Greek letters: α, β, γ, μ, v, ξ, π, ω, χ. The type of cations present (K+, NH4+, Na+, Mg2+, Ca2+) also influences the solubility of the carrageenans.
Polyacrylates are also advantageous gelators to use for the purposes of the present invention. Polyacrylates which are advantageous according to the invention are acrylate-alkyl acrylate copolymers, in particular those selected from the group of carbomers or Carbopols (Carbopol® is actually a registered trademark of the BF Goodrich Company). In particular, 30 the acrylate-alkyl acrylate copolymer(s) which are advantageous according to the invention is/are characterized by the following structure:
2015258133 21 Aug 2019
In the above, R’ is a long-chain alkyl moiety and x and y are numbers which symbolize the respective stoichiometric proportion of each of the comonomers.
According to the invention, particular preference is given to acrylate copolymers and/or acrylate alkylacrylate copolymers which are available under the trade names Carbopol® 1382, Carbopol® 981 and Carbopol® 5984 from the BF Goodrich Company.
Furthermore, particularly advantageous are copolymers of C10-30 alkyl acrylates and one or more monomers of acrylic acid, methacrylic acid or esters thereof which are crosslinked with an allyl ether of sucrose or an allyl ether of pentaerythritol.
Particularly advantageous are compounds carrying the INCI name acrylates/C 10-30 alkyl acrylate crosspolymer. Particularly advantageous are those available under the trade names Pemulen TR1 and Pemulen TR2 from the BF Goodrich Company.
Further particularly advantageous are ammonium acryloyldimethyltaurate/vinylpyrrolidone copolymers, in particular those having the empirical formula [C7Hi6N2SO4]n [C6HgNO]m, corresponding to a statistical structure as follows:
2015258133 21 Aug 2019
Preferred species for the purposes of the present invention are archived in the Chemical Abstracts under the registry numbers 58374-69-9, 13162-05-5 and 88-12-0, and available under the trade name Aristoflex® AVC from Clariant GmbH.
The advantageous total amount of one or more hydrocolloids in the finished cosmetic or dermatological preparations according to the invention is in the range of 0.005 to 5 wt.%, preferably between 0.1 and 2.0 wt.%, and in particular between 0.25 and 0.75 wt.%, in each case based on the total weight of the outer, flowable, gelatinous, water-based phase.
The polymer matrix, which represents as it were the backbone of the particulate phase can be selected from among the group of conventional cosmetically or dermatologically tolerated, substantially water-insoluble polymeric substances by way of example selected from among the group of the following substances: algin, carrageenan, agar, gellan gum, chitosan.
Particular advantageous is a matrix of alginates, preferably sodium alginates, as are also used in DE 44 24 998 A1.
Metal oxide pigments which are preferred according to the invention are, in particular, oxides of titanium (TiO2), zinc (ZnO), iron (e.g. Ce2O3), mixed oxides of the corresponding metals 20 and mixtures of such oxides, and the sulfate of barium (BaSCU).
It is particularly advantageous to use oxides of titanium (T1O2) as metal oxide pigments which are particularly preferred according to the invention.
2015258133 21 Aug 2019
The pigments can also be advantageously used for the purposes of the present invention in the form of commercially available oily or aqueous predispersions. Dispersants and/or solubilizers can advantageously be added to these predispersions.
According to the invention, the pigments can advantageously be surface-treated (coated), wherein a hydrophilic, amphiphilic or hydrophobic character should be formed or retained, by way of example. This surface treatment can consist of equipping the pigments according to methods known per se with a thin hydrophilic and/or hydrophobic inorganic and/or organic layer. The various surface coatings can for the purposes of the present invention also contain 0 water.
Inorganic surface coatings for the purposes of the present invention can consist of aluminum oxide (AI2O3), aluminum hydroxide AI(OH)3 or aluminum oxide hydrate (also: alumina, CAS no. 1333-84-2), sodium hexametaphosphate (NaPO3)6, sodium metaphosphate (NaPO3)n, silicon dioxide (S1O2) (also: silica CAS no. 7631 -86-9) or iron oxide (Fe2O3). These inorganic surface coatings can occur alone, in combination, and/or in combination with organic coating materials.
Organic surface coatings for the purposes of the present invention can consist of vegetable or animal aluminum stearate, vegetable or animal stearic acid, lauric acid, dimethylpolysiloxane (also: dimethicone), methylpolysiloxane (methicone), simethicone (a mixture of dimethylpolysiloxane with an average chain length of 200 to 350 dimethylsiloxane units and silica gel) or alginic acid. These organic surface coatings can occur alone, in combination, and/or in combination with inorganic coating materials.
Zinc oxide particles and predispersions of zinc oxide particles which are suitable according to the invention are available under the following trade names from the companies listed:
Trade name | Coating | Manufacture r |
Z-Cote HP1 | 2% Dimethicone | BASF |
Z-Cote | / | BASF |
ZnO NDM | 5% Dimethicone | H & R |
ZnO Neutral | / | H & R |
MZ 505 M | 5% Methicone | Tayca Corp. |
Suitable titanium dioxide particles and predispersions of titanium dioxide particles are available under the following trade names from the companies listed:
2015258133 21 Aug 2019
Trade name | Coating | Manufacturer |
MT-100TV | aluminum hydroxide/stearic acid | Tayca Corporation |
MT-100Z | aluminum hydroxide/stearic acid | Tayca Corporation |
Eusolex T-2000 | Alumina/Simethicone | Merck KgaA |
Titanium dioxide T805 (Uvinul T1O2) | Octyltrimethylsilane | Degussa |
Tioveil AQ 10PG | Alumina/Silica | Solaveil/Uniquema |
A310 Tudor Aspen - Kingfisher Colours Ltd.
Kronos 1171 - Kronos Worldwide, Inc.
According to the invention, advantageous UV filter substances are, for example, dibenzoylmethane derivatives, in particular 4-(tert-butyl)-4'-methoxydibenzoylmethane (CAS 0 no.70356-09-1), which is sold by DSM under the brand Parsol® 1789 and by Merck under the trade name Eusolex® 9020.
Other advantageous UV filter substances for the purposes of the present invention are sulfonated, water-soluble UV filters - by way of example:
• phenylene-1,4-bis-(2-benzimidazyl)-3,3'-5,5'-tetrasulfonic acid and its salts, particularly the corresponding sodium, potassium or triethanolammonium salts, in particular phenylene-1,4-bis-(2-benzimidazyl)-3,3'-5,5'-tetrasulfonic acid bis-sodium salt with the INCI name Bisimidazylate (CAS no. 180898-37-7), which is available, for example, under the trade name Neo Heliopan AP from Haarmann & Reimer;
• salts of 2-phenyl benzimidazole-5-sulfonic acid, such as its sodium, potassium or its triethanolammonium salt, and the sulfonic acid itself with the INCI name Phenylbenzimidazole sulfonic acid (CAS. No. 27503-81-7) which is available for example under the trade name Eusolex 232 from Merck or under Neo Heliopan Hydro from Haarmann & Reimer;
• 1,4-di(2-oxo-10-sulpho-3-bornylidenemethyl)benzene (also: 3,3'( 1,4phenylendimethylene)-bis-(7,7-dimethyl-2-oxo-bicyclo-[2.2.1]hept-1-ylmethane sulfonic
2015258133 21 Aug 2019 acid) and its salts (particularly the corresponding 10-sulfatocompounds, especially the corresponding sodium, potassium or triethanolammonium salt), also known as benzene1,4-di(2-oxo-3-bornylidenemethyl-10-sulfonic acid). Benzene-1,4-di(2-oxo-3bornylidenemethyl-10-sulfonic acid) has the INCI name terephthalidene dicamphor sulfonic acid (CAS no. 90457-82-2) and is, for example, available under the trade name
Mexoryl SX from the company Chimex;
• sulfonic acid derivatives of 3-benzylidenecamphor, such as, for example, 4-(2-oxo-3bornylidenemethyl)benzenesulfonic acid, 2-methyl-5-(2-oxo-3bornylidenemethyl)sulfonic acid, and salts thereof.
Advantageous UV filter substances for the purposes of the present invention are also socalled broadband filters i.e., filter substances which absorb both UV-A and UV-B radiation.
Advantageous broadband filters or UV-B filter substances are, for example, triazine derivatives, by way of example • 2,4-bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6(4-methoxyphenyl)-1,3,5-triazine (INCI: methylene bis-benzotriazolmethylbutylphenol), which is available from CIBAChemikalien GmbH under the trade name Tinosorb® S;
• dioctylbutylamidotriazone (INCI: diethylhexylbutamidotriazone), which is available under the trade name UVASORB HEB from Sigma 3V;
• 4,4',4-(1,3,5-triazine-2,4,6-triyltriimino)-tris-benzoic acid-tris(2-ethylhexylester), also: 2,4,6-tris[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: octyl triazone), marketed by BASF Aktiengesellschaft under the trade name UVINUL® T 150.
An advantageous broadband filter for the purposes of the present invention is also 2,2'methylene-bis (6(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)-phenol) (INCI: bisoctyltriazole), which is available under the trade name Tinosorb® M from CIBAChemikalien GmbH.
An advantageous broadband filter for the purposes of the present invention is also 2-(2Hbenzotriazole-2-yl)-4-methyl-6[2-methyl-3-[1,3,3,3-tetramethyl-1[(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol (CAS no. 155633-54-8) with the INCI name drometrizole trisiloxane.
2015258133 21 Aug 2019
The further UV filter substances can be oil-soluble. Advantageous oil-soluble filter substances are, by way of example:
3-benzylidenecamphor derivatives, preferably 3-(4-methylbenzylidene) camphor, 3benzylidene camphor;
4-aminobenzoic acid derivatives, preferably 4-(dimethylamino)-benzoic acid-(2ethylhexyl)ester, 4-(dimethylamino)benzoic acid amylester;
derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone, and UV filters bonded to polymers.
A further photoprotective filter substance to be used advantageously according to the invention is ethylhexyl-2-cyano-3,3-diphenylacrylate (octocrylene), which is available under the name Uvinul ® N 539 from BASF.
Particularly advantageous preparations for the purposes of the present invention contain, in addition to the filter substance(s), preferably also further UV-A and/or broadband filters, in particular dibenzoylmethane derivatives [for example 4-(tert-butyl)-4'methoxydibenzoylmethane] and/or 2,4-bis-{[4-(2-ethylhexyloxy)-2-hydroxy]-phenyl}-6-(4methoxyphenyl)-1,3,5-triazine, each either alone or in any combination with each other.
The list of said UV filters which can be used for the purposes of the present invention is naturally not intended to be exhaustive.
The particulate phase advantageously contains a total amount of the substances which absorb UV radiation in the UV-A and/or UV-B-range of, by way of example, 0.1 wt.% to 30 wt.%, preferably 0.5 to 20 wt.%, in particular 1.0 to 15.0 wt.%, each based on the total weight of the particulate phase.
It is possible and optionally advantageous according to the invention, although not obligatory, to equip not only the particulate phase but also the outer, flowable, gel-based phase with UV filter substances, as long as the requirements for turbidity are met. Typically, water-soluble UV filter substances are used in the outer gel phase.
Where water-soluble UV filter substances will be used in the outer gel phase, the same contains a total amount of substances which absorb UV radiation in the UV-A and/or UV-B23
2015258133 21 Aug 2019 range of 0.1 wt.% to 30 wt.%, preferably 0.5 to 20 wt.%, more preferably 1.0 to 15.0 wt.%, each based on the total weight of the outer gel phase.
To produce the particles which constitute the inner, solid, particulate phase, a method which is known from DE 44 24 998 A1 can be used advantageously. In this method, the composition constituting the particulate phase, and optionally a composition from which the particulate phase will develop, and which is preferably in a flowable form, is formed into a liquid jet directed into the environment which has the curing effect, and the portions are formed by the liquid jet being divided before the curing environment into defined portions, such that the portions continue to move substantially in the direction of the liquid jet.
This method can currently be designed in such a manner that a liquid jet is initially formed from the composition which composes the particulate phase, or optionally a composition from which the particulate phase will develop, by the liquid particles moving in the direction of the environment which produces the curing effect. After formation of the liquid jet, the same is mechanically divided into defined portions, wherein the accordingly formed portions continue to move in the direction determined by the liquid jet. The division of the liquid jet is thus carried out by periodically removing liquid from the liquid jet, thereby forming the defined portions. The length of these portions can be kept so short that during the remaining movement up to the environment which produces the curing effect, in particular the surface of a curing medium, an at least approximately spherical shape is formed due to the surface tension of the liquid medium, such that spherical particles are formed.
For liquid media which have a certain viscosity, it is advantageous if the liquid medium is forced through the nozzle to form the liquid jet. This is usually done by applying an overpressure in the reservoir and/or in the line to the liquid jet nozzle.
In many applications there is a need to equip the preferably spherical particles with a coating. This coating can optionally be cured in the same environment. It is possible according to the 30 present invention to coat the portions of the liquid medium prior to curing by generating at least one liquid cross-jet with a liquid which is suitable for coating, wherein the portions pass through the same.
The liquid cross-jet can be expediently designed as a flat jet, such that the possible passage 35 area is enlarged for the portions.
2015258133 21 Aug 2019
A modification of the method can involve the nozzle arrangement being configured to form at least one liquid jet, and a movable dividing device being arranged below the nozzle arrangement for the at least one liquid jet.
The dividing device in this case can be partly positioned directly at the outlet of the nozzle arrangement. Preferably, the moving dividing device can be driven with rotation, and is equipped with elements which interrupt the liquid jet. The rotating drive of the dividing device enables a particularly simple construction of the device according to the invention.
In one advantageous embodiment, the elements which interrupt the liquid jet can be radiallyoriented radiant elements which are implemented as wires, plastic threads, or the like. The elements can be designed without inherent shape stability, only obtaining their radial orientation upon the rotation of the first dividing device. In another embodiment, a rotating disk can be used which has passage openings arranged tightly next to each other on a radius for the liquid jet. The struts between the passage openings in this case form the elements which interrupt the liquid jet.
The dividing device is advantageously surrounded by a cylindrical housing which is open at least in the area of the liquid jet, and which has a capturing recess to capture liquid which 0 runs off the housing wall. In this manner, the liquid conveyed outward radially by the elements interrupting the liquid jet can be captured and directed back to the associated reservoir. The capturing recess is preferably formed by a circumferential groove which is configured with a drain.
To form a coating of the particles as mentioned above, the device can have a cross nozzle arranged downstream of the dividing device with respect to the liquid jet, oriented at an angle to the liquid jet and connected to a reservoir for a liquid which is suitable for coating. The cross nozzle in this case can embody a flat jet nozzle.
In an exemplary embodiment, a liquid jet of a cell emulsion in a sodium alginate solution can exit the nozzle, and the cross jet can be formed by a cell-free sodium alginate solution, while a CaCk solution fills the capturing container 5 as the curing medium.
Upon passage through the cross jet which is preferably designed as a flat beam, the liquid 35 portions which contain the cells are coated with the cell-free alginate solution for 3 min. and
2015258133 21 Aug 2019 then crosslinked immediately so that a migration of cells from the core into the coating layer cannot occur - since the Ca ions are able to diffuse much faster into the alginate droplets than the cells can move.
It is possible to equip a conventional cosmetic container with a preparation according to the invention in such a manner that the inner particulate phase approaches the densest possible packing of spheres (space-filling, cubic close packing of spheres: about 74%), the interstitia of which are filled by the outer, aqueous, gel phase.
However, this is not always desired, and does not always have practical advantages. Therefore, the volume ratio of the inner particulate phase to the outer, aqueous gel is preferably in the range of about 20% : 80% to 50% : 50%.
Preparations according to the invention can be packaged in a visually attractive and advantageous manner and in this further aspect, also inventively per se in a container (B),
- which has a tubular body (K),
- the wall (Wk) of which allows the transmission of visible light of 25% to about 100%,
- wherein a dispensing head (SK) is attached to the upper end thereof,
- which is bounded on the bottom by a movable trailing piston (SCH).
The dispensing head (SK) can particularly advantageously have
- an outer actuating element (BE) with a dispensing opening (SPO) which is closed off by a check valve (RV),
- a base unit (BO) which lies on the tubular body (K), having an opening (Ο) to the tubular body, and
- a flexible, inner, substantially cylindrical, molded hollow body (H) with bellows-like walls (Wh), wherein the elements of the dispenser head are designed in such a manner that
- the hollow body (H) has openings (Oo), (Ou) on each of the two ends (So), (Su),
- the hollow body (H) lies with its lower end face (Su) on the base unit (BO), and wherein the opening (Ο) thereof and the lower opening (Ou) of the hollow body (H) are positioned one above the other, in such a manner that, when
2015258133 21 Aug 2019
- the actuating element (BE) compresses the inner hollow body (H) in the direction of its longitudinal axis as a result of external pressure,
- the substance situated inside the hollow body (H) is conveyed out of the container (B) through the check valve (RV) and the dispensing head (SK), and
- when the external pressure ceases, the return force of the flexible inner hollow body (H) suctions substance out of the tubular body (K) and into the flexible inner hollow body (H).
Fig. 1 shows an inventively advantageous container (B),
- which has a tubular body (K),
- wherein a dispensing head (SK) is attached to the upper end thereof,
- which is bounded on the bottom by a movable trailing piston (SCH), and
- which has a dispenser head (SK), wherein in Fig. 1a, the container (B) is illustrated as separated into the body (K) and the dispenser head (SK) (in this case configured with an additional closure cap which is not indicated).
Fig. 1a shows a dispenser head (SK),
- which has an outer actuating element (BE) with a dispensing opening (SPO) which is closed off by a check valve (RV),
- a base unit (BO) which lies on the tubular body (K), having an opening (0) to the tubular body, and
- a flexible, inner, substantially cylindrical, molded hollow body (H) with bellows-like walls (Wh).
Fig. 1 b shows a perspective view of an embodiment of the flexible, inner, substantially cylindrical, molded hollow body (H),
- with bellows-like walls (Wh),
- wherein the lower end face (Su) and the opening (Ou) thereof are visible.
Fig. 1c shows the outline of one embodiment of the flexible, inner, substantially cylindrical, molded hollow body (H),
- with bellows-like walls (Wh), wherein the elements of the dispenser head are designed in such a manner that
2015258133 21 Aug 2019
- the hollow body (H) has openings (Oo), (Ou) on each of the two ends (So), (Su), and wherein the hollow body (H) is designed in such a manner that the lower opening (OU) on the lower end (SU) comprises a device (V) which divides the substance stream from the interior of the tubular body (K) into the hollow body into a plurality of partial streams.
Fig. 1d shows a device (V), which is included for the purpose of dividing the substance stream from the interior of the tubular body (K) (not shown here) into the hollow body (H) (not shown here) into three partial streams by means of three passage openings (Du).
In the preparations according to the invention the ubiquinone(s) and/or plastoquinone(s) are optimally protected against oxidation and the harmful effects of UV radiation.
When the preparations are applied to a surface, the inventive preparations are rubbed into a homogeneous emulsion which absorbs quickly into the skin and is visually and sensually very appealing.
It is particularly surprising that, when a dispenser is used, the shear forces at the dispenser output are adequate to transform the originally into separate compartments (that is, the outer gel phase and the inner particulate phase) into an optically homogeneous entity.
The cosmetic and dermatological preparations according to the invention can comprise cosmetic excipients such as are customarily used in such preparations - by way of example preservatives, preservation aids, bactericides, perfumes, substances for preventing foaming, dyestuffs, pigments which have a coloring action, thickeners, moisturizing and/or humectant 25 substances, fillers which improve the skin feel, fats, oils, waxes, or other customary constituents of a cosmetic or dermatological preparation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
Advantageous preservatives for the purposes of the present invention are, for example, 30 formaldehyde donors (such as, for example, DMDM hydantoin, which is available, for example, under the trade name Glydant™ from the Lonza company), iodopropylbutyl carbamates (e.g. sold under the trade names Glycacil-L, Glycacil -S available from the Lonza company, and/or Dekaben LMB from Jan Dekker), parabens (that is, p-hydroxy benzoic acid alkyl esters such as methyl, ethyl, propyl and/or butylparaben), phenoxyethanol, ethanol,
2015258133 21 Aug 2019 benzoic acid and the like. Typically, the preservative system according to the invention further advantageously comprises preservation aids such as octoxyglycerol, glycine soya etc.
Particularly advantageous preparations are also obtained when antioxidants are used as additives or active agents. According to the invention, the preparations advantageously comprise one or more antioxidants. Favorable, but nevertheless optional, antioxidants can include all antioxidants which are suitable or customary for cosmetic and/or dermatological applications.
Particularly advantageous for the purposes of the present invention is the use of watersoluble antioxidants, such as vitamins - by way of example ascorbic acid and derivatives thereof, as well as D-biotin, natural and/or synthetic isoflavonoids, alpha-glucosylrutin, panthenol, aloe vera, honokiol, magnolol.
The amount of antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30 wt.%, particularly preferably 0.05 to 20 wt.%, especially 0.1 to 10 wt.%, based on the total weight of the preparation.
It is particularly advantageous if the cosmetic preparations according to the present invention contain cosmetic or dermatological active agents, wherein preferred active agents are antioxidants which can protect the skin against oxidative stress.
Advantageous further active agents are natural active agents and/or derivatives thereof such as phytoene, carnitine, carnosine, creatine, N-acetyl-hydroxyproline, taurine and/or betaalanine.
The outer, aqueous gel phase of the preparations according to the invention can advantageously contain conventional cosmetic excipients such as alcohols, in particular those of low carbon number, preferably ethanol and/or isopropanol, diols or polyols of low carbon number, and ethers thereof, preferably propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethylether or -monobutylether, propylene glycol monomethyl-, monoethylor monobutylether, diethylene glycol monomethylor monoethylether, and analogous products, polymers, foam stabilizers, electrolytes, and especially one or more thickeners, which can advantageously be selected from among the group silica, aluminum silicates, polysaccharides or derivatives thereof, for example hyaluronic acid, xanthan gum, hydroxypropyl methylcellulose, particularly advantageously from among the group of
2015258133 21 Aug 2019 polyacrylates, preferably a polyacrylate from among the group of Carbopols, for example Carbopol grades 980, 981, 1382, 2984, 5984, either individually or in combination. Moisturizers can also preferably be used.
Moisturizers are substances or mixtures of substances which impart to cosmetic or dermatological preparations the property of reducing moisture loss by the horny layer (also called transepidermal water loss (TEWL)) and/or positively influencing the hydration of the horny layer following application or distribution on the skin surface.
Advantageous moisturizers for the purposes of the present invention are, for example, glycerol, lactic acid and/or lactates, in particular sodium lactate, butylene glycol, propylene glycol, biosaccharide gum-1, glycine soja, ethylhexyloxyglycerin, pyrrolidone and urea. Furthermore, it is particularly advantageous to use polymeric moisturizers from the group of polysaccharides which are water-soluble and/or water-swellable, and/or can gel with the aid of water. Particularly advantageous are, byway of example, hyaluronic acid, chitosan and/or a fucose-rich polysaccharide, which is filed in the Chemical Abstracts under the registry number 178463-23-5, and is available, byway of example, under the name of fucogel® 1000 from SOLABIA S.A.
The cosmetic or dermatological preparations according to the invention can also advantageously, but not necessarily, comprise fillers which further improve, for example, the sensory and cosmetic properties of the formulations and bring about or enhance a velvety or silky feel on the skin, for example. Advantageous fillers for the purposes of the present invention are starch and starch derivatives (such as tapioca starch, distarch phosphate, aluminum and/or sodium starch octenyl succinate and the like), pigments which have neither primarily UV filter effect nor a coloring effect (for example, boron nitride, etc.) and/or Aerosile® (CAS no. 7631-86-9).
The following examples illustrate the present invention without limiting it. The numerical values in the examples are percentages by weight, based on the total weight of the preparations.
o CO
Examples, inner particulate phase:
Variants | LU | in | 0.2 | 0.3 | C\l | OO | C\l | C\l | 0.4 | 0.6 | 0.5 | C\l | ad 100 | |
Q | in | 0.13 | C\l | 00 | C\l | 00 | 00 o | 0.6 | 0.5 | C\l | ad 100 | |||
O | in | 0.25 | 0.5 | IO | IO | 0.5 | o | 0.6 | 0.6 | 0.5 | C\l | ad 100 | ||
00 | in | o | IO | IO | - | 0.49 | 0.6 | 0.5 | C\l | ad 100 | ||||
< | in | 0.19 | 2.50 | 10.00 | 10.00 | 0.25 | 8.00 | 1.00 | 0.60 | 0.50 | 2.00 | ad 100 | ||
INCI | Algin | Ubiquinone | Cl 77891 | Cyclomethicone (BRB CM 56; BRB International) | Cyclomethicone + Dimethiconol (Xiameter PMX 1501 Fluid; Dow Corning) | Sodium stearyl glutamate (Eumulgin SG; BASF Personal Care and Nutrition) | Polyglyceryl-3 methylglucose distearate (Tego Care 450; Evonik Industries) | Polymethylsilsesquioxane (Gransil PSQ; Grant Industries) | Fragrance | Phenoxyethanol | 1,2-Hexanediol | Methylpropanediol | Water |
The ingredients of the recipe of Examples A to E are prepared as in the experimental example in DE 44 24 998, column 5, and formed into essentially spherical particles with a diameter of approximately 6 mm.
6tOZWt£ ££18£Z$IOZ co
co | Ζ0Ό | 0.02 | 0.4 | 00 d | 22 | id | co CD | 0.6 | 0.5 | CM | 1.63 | ID | ad | 100 | ||||||
LT) | ||||||||||||||||||||
o | o | CM | ip | id | o | 00 | CD | ID | O | o | ||||||||||
h- | d | d | d | d | d | d | d | CM | 1 | 1 | 1 | d | ra | |||||||
h- | CM | co | ||||||||||||||||||
o | o | 00 | CM | CD | CD | CD | ID | O | o | |||||||||||
<0 | d | d | d | d | CM | id | d | d | CM | 1 | 1 | CM | 1 | ID | ra | |||||
id | ||||||||||||||||||||
o | o | CM | id | id | o | 00 | CD | CD | O | o | ||||||||||
m | d | d | d | d | d | d | d | CM | 1 | 1 | CM | 1 | ra | |||||||
h- | CM | co | co | |||||||||||||||||
o | o | 00 | CM | CD | CD | CD | CD | O | o | |||||||||||
'’t | d | d | d | d | CM | id | d | d | CM | 1 | 1 | 1 | ID | ra | ||||||
id | ||||||||||||||||||||
o | o | CM | id | id | o | 00 | CD | CD | h. | O | o | |||||||||
co | d | d | d | d | d | d | d | CM | 1 | d | 1 | 1 | ra | |||||||
h- | CM | co | CO | |||||||||||||||||
o | o | 00 | CM | CD | CD | CD | co | O | o | |||||||||||
(Λ Μ-» | CM | d | d | d | d | CM | id | d | d | CM | CM | 1 | 1 | 1 | ID | ra | ||||
c | ||||||||||||||||||||
π | ||||||||||||||||||||
id | 00 | |||||||||||||||||||
π | o | o | CM | ip | id | o | 00 | CD | CD | CM | O | o | ||||||||
> | d | d | d | d | d | d | d | CM | 1 | 1 | 1 | ra | ||||||||
O | ||||||||||||||||||||
c | (/) | |||||||||||||||||||
ra | c | c | ||||||||||||||||||
cd | .Φ | ra | — | |||||||||||||||||
TD | l | (/) | ||||||||||||||||||
o | CD | ra | ra | |||||||||||||||||
sonal < | ; Merc | CD) C >> M—· | O O > | b M—· ra | ||||||||||||||||
L_ | ra | < | ||||||||||||||||||
cd CL | co | o Φ | X CD | Ό Φ Q | ||||||||||||||||
1 1 | co | CD. | M— | C | ||||||||||||||||
ISV | o | U) Ό | o M—· W | ra > XD | ||||||||||||||||
m | o z | c cu | < | < | ||||||||||||||||
o | _c | O | ||||||||||||||||||
ai | (/) | CD | N | |||||||||||||||||
o | < | < | E | _Q | (/) M—· | |||||||||||||||
in C | CD M—· ra | o o | CD | o CD. | O _1 | c .Φ TD | ||||||||||||||
CD | 1 | E | C) | Φ | ||||||||||||||||
(Eumul | TD >> _c LCD ID | Οχ d M—· ra | >o o Q_ (/) (/) o | o CL £ CD | 00 CD) O CD. CD | b) c >> M—· | ||||||||||||||
CD | CU | _Q | CU | |||||||||||||||||
o | Ξ) | O | o | |||||||||||||||||
c | ra | CD M—· | cu | CU o | CD CD. | |||||||||||||||
gel | bea | Ό E | CD E | CU | _c | b | ω σ | |||||||||||||
(/) | o | o | φ | o | c | |||||||||||||||
o Φ | cd M—· | casto | TD O (/) | 0s· m | o Q_ (/) (/) Q | cu >o cu | E d >> | co O) o n | _cu .c. (/) < | |||||||||||
xample, outer aq | INCI | reatine | reatinine | odium hyalurona | EG-40 hydrated | utrition) | lycerin | ,2-Propanediol | odium citrate (Tr | CD TO X o TO >> _c E Ξ3 d o | o c cu _c M—· CD >> X o c CD _C | o d CD c ra X CD T CM | O d CD C ra CD. o Q. >> _c M—· CD | b CL £ O Ό cu o b | o co ό O ~5) CD M—· ra >> b | o CD ra E Ξ5 d o E E | CD .Q b o b E CD .Q b | cd CD LL δ CD 'ra' .b | b M—· ra | |
LU | O | O | ω | CL | z | O | -1- | ω | ω | CL | -1- | < | < | < | o | —1 |
6tO7Wt7 ££18979107
The recipe ingredients in Examples 1-8 are stirred into a mixture at 25 °C until clear gels have formed.
Particles and gels were combined in various volume ratios with each other, as in the following examples. The first value indicates the particulate φ ω ra ΙΞ Q.
CD CD
CD ω CD
O C
CD ω ra ΙΞ Q.
00 | 50 : 50 | 25 : 75 | 40 : 60 | 50 : 50 | 35 : 65 | |||||
o | uo | o | o | o | ||||||
CD | CD | uo | r- | CD | ||||||
O | UO | o | o | O | ||||||
h- | CO | uo | co | |||||||
o | uo | uo | o | uo | ||||||
CD | CD | h- | CD | CD | ||||||
O | UO | uo | O | UO | ||||||
CD | CO | CM | CO | |||||||
LCO | o | uo | o | o | ||||||
h- | CD | CD | h- | CD | ||||||
LCO | O | UO | o | O | ||||||
LCD | CM | CO | co | |||||||
O | o | o | uo | uo | ||||||
CD | h- | uo | CD | CD | ||||||
O | o | o | uo | UO | ||||||
co | uo | co | CO | |||||||
o | uo | o | uo | o | ||||||
LCO | h- | CD | CD | uo | ||||||
o | uo | o | UO | o | ||||||
co | LCO | CM | CO | uo | ||||||
o | o | o | uo | uo | ||||||
h- | CD | CD | CD | CD | ||||||
o | O | O | UO | uo | ||||||
C\l | co | CO | co | |||||||
uo | o | o | o | uo | ||||||
h- | h- | uo | CD | h- | ||||||
uo | o | o | O | uo | ||||||
CM | co | uo | CM | |||||||
CQ | o | Q | LU |
In charges of 40 ml, the preparations A1-E8 were filled into containers as described in Figure 1a to Figure 1d.
6tO7Wt7 ££18979107
2015258133 21 Aug 2019
Claims (3)
- Claims1. A cosmetic preparation, comprising:5 an outer, flowable, gelatinous, water-based phase comprising water and one or more hydrocolloids, which has a viscosity in the range of 1,000 to 10,000 mPas at a temperature of 25 °C and a shear rate of about 10s'1, and which allows the transmission of light of the wavelength 700 nm in the range of at least 30%, and10 an inner, solid, particulate phase comprising substantially spherical particles with an average diameter in the range of 0.1 to 10 mm and comprising: a polymer matrix which is substantially insoluble in water and one or more light filter substances which is selected from among the group of metal oxide pigments.15 2. A cosmetic preparation according to claim 1, wherein the outer, flowable, gelatinous, water-based phase which has a viscosity in the range of 3,000 to 9,000 mPas at a temperature of 25 °C and a shear rate of about 10s'1.3. A cosmetic preparation according to claim 1, wherein the outer, flowable, gelatinous,20 water-based phase which has a viscosity in the range of 5,000 to 8,000 mPas at a temperature of 25 °C and a shear rate of about 10s'1.4. A cosmetic preparation according to any one of claims 1 to 3 wherein the spherical particles have an average diameter in the range of 2 to 7.5mm5. A cosmetic preparation according to any one of the preceding claims wherein the hydrocolloid is selected from among the group consisting of celluloses/methyl celluloses, polyacrylates and mixtures thereof.30 6. A cosmetic preparation according to any one of the preceding claims wherein the hydrocolloid is selected from the group consisting of carrageenan, xanthan, acrylate/C 10-30 alkyl acrylate crosspolymers, ammoniumacryloyldimethyltaurate/vinylpyrrolidone copolymers and mixtures thereof.2015258133 21 Aug 20197. A cosmetic preparation according to any one of the previous claims, wherein the total amount of one or more hydrocolloids is less than 1.5 wt.% with respect to the total weight of the preparations.5 8. A cosmetic preparation according to any one of the previous claims, wherein the total amount of one or more hydrocolloids is between 0.1 and 1.0 wt.%, with respect to the total weight of the preparations.9. A cosmetic preparation according to any one of the previous claims, wherein the10 polymer matrix of the inner particulate phase is selected from among the group consisting of the following polymer matrices: algin/alginate, carrageenan, agar, gellan gum, chitosan or mixtures thereof.10. A cosmetic preparation according to any one of the previous claims, wherein the metal15 oxide pigment is selected from among the group of oxides of titanium (T1O2), zinc (ZnO), iron (e.g. Fe2O3), zirconium (ZrO2), silicon (S1O2), manganese (e.g. MnO), aluminum (AI2O3), cerium (e.g. Ce2O3), mixed oxides of the corresponding metals and mixtures of such oxides, barium sulfate (BaSO4) and mixtures thereof.20 11. A cosmetic preparation according to claim 10, wherein the one or more metal oxide pigments is titanium oxide (T1O2).12. A cosmetic preparation according to any one of the previous claims, wherein ubiquinone 10 (coenzyme Q10) is selected as the ubiquinone.13. A cosmetic preparation according to claim 12, wherein the ubiquinone is provided in its reduced form as ubiquinol.14 A cosmetic preparation according to any one of the previous claims, wherein the30 photoprotective filter substance or substances in the particulate phase is selected from among the group of octylmethoxycinnamates, octocrylene, bisoctrizole, bemotrizinol, drometrizole trisiloxane, benzophenone-3, benzophenone-4 and mixtures thereof.15. A cosmetic preparation according to any one of the previous claims, wherein the35 volume ratio of the inner particulate phase to the outer, aqueous gel is in the range from about 20% : 80% to 74% : 26%.2015258133 21 Aug 201916. A cosmetic preparation according to any one of the previous claims, wherein the volume ratio of the inner particulate phase to the outer, aqueous gel is in the range from about 30% : 70% to 65% : 35%.17. A cosmetic preparation according to any one of the previous claims, wherein the volume ratio of the inner particulate phase to the outer, aqueous gel is in the range from about 40% : 60% to 60% : 40%.WO 2015/169454PCT/EP2015/0524151/4Fig. 1 aWO 2015/169454PCT/EP2015/052415
- 2/4Fig. 1 bWhFig. 1 c hWhWO 2015/169454PCT/EP2015/052415
- 3/4Fig. 1 dVDuIDuDuWO 2015/169454
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102014208438.5 | 2014-05-06 | ||
DE202014003722.1U DE202014003722U1 (en) | 2014-05-06 | 2014-05-06 | Pearl-shaped cosmetic dosage forms |
DE102014208438.5A DE102014208438A1 (en) | 2014-05-06 | 2014-05-06 | Pearl-shaped cosmetic dosage forms |
DE202014003722.1 | 2014-05-06 | ||
PCT/EP2015/052415 WO2015169454A1 (en) | 2014-05-06 | 2015-02-05 | Bead-shaped cosmetic dosage forms |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2015258133A1 AU2015258133A1 (en) | 2016-11-24 |
AU2015258133B2 true AU2015258133B2 (en) | 2019-09-12 |
Family
ID=52446383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015258133A Active AU2015258133B2 (en) | 2014-05-06 | 2015-02-05 | Bead-shaped cosmetic dosage forms |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3139896A1 (en) |
AU (1) | AU2015258133B2 (en) |
BR (1) | BR112016025474A2 (en) |
WO (1) | WO2015169454A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110974715B (en) * | 2019-12-26 | 2023-08-01 | 常州纳欧新材料科技有限公司 | APG modified MBBT composite material and preparation method of aqueous slurry thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19537027A1 (en) * | 1995-10-05 | 1997-04-10 | Beiersdorf Ag | Skin care product for old skin |
JP2003504318A (en) * | 1999-07-13 | 2003-02-04 | ファルマソル ゲーエムベーハー | UV radiation reflectors or absorbers that protect against harmful UV radiation and enhance the natural skin barrier |
DE60211581D1 (en) * | 2001-03-23 | 2006-06-29 | Oreal | Skin treatment agent containing fibers and ubiquinones |
JP4994640B2 (en) * | 2005-11-07 | 2012-08-08 | 岩瀬コスファ株式会社 | UV-absorbing composite powder |
EP2218447B1 (en) * | 2008-11-04 | 2017-04-19 | PharmaSol GmbH | Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles |
DE102012211790A1 (en) * | 2012-07-06 | 2014-01-09 | Beiersdorf Ag | Cosmetic composition comprises behenyl alcohol, homomenthyl salicylate, and a photosensitive active substance |
EP2708264B1 (en) * | 2012-09-13 | 2017-10-04 | PM-International AG | Cosmetic two component preparation for separate storage of compositions comprising liposomes of coenzyme Q10 and fluorocarbons |
KR101342958B1 (en) * | 2013-08-08 | 2013-12-18 | (주)바이오제닉스 | Triple layered capsule using water-nonsoluble substance, manufacturing mehtod thereof and cosmetic preparations using it |
-
2015
- 2015-02-05 BR BR112016025474A patent/BR112016025474A2/en active Search and Examination
- 2015-02-05 AU AU2015258133A patent/AU2015258133B2/en active Active
- 2015-02-05 EP EP15702506.5A patent/EP3139896A1/en not_active Withdrawn
- 2015-02-05 WO PCT/EP2015/052415 patent/WO2015169454A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
BR112016025474A2 (en) | 2017-08-15 |
AU2015258133A1 (en) | 2016-11-24 |
EP3139896A1 (en) | 2017-03-15 |
WO2015169454A1 (en) | 2015-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2426601T3 (en) | Cosmetic formula with glycosyl glycerides and powdered raw materials | |
US20070031348A1 (en) | Use of oxygen in cosmetic or dermatological preparations | |
EP2942045B1 (en) | Bead-shaped cosmetic dosage forms | |
AU2015258135B2 (en) | Cosmetic product | |
EP1837007A2 (en) | Sprayable sun protection lotion | |
DE202014003722U1 (en) | Pearl-shaped cosmetic dosage forms | |
DE10305965A1 (en) | Cosmetic or dermatological composition used e.g. for rejuvenating and revitalizing skin, promoting skin metabolism and combating wrinkles contains 8-hexadecene-1,16-dicarboxylic acid | |
AU2015258133B2 (en) | Bead-shaped cosmetic dosage forms | |
DE102014208450B4 (en) | Cosmetic product | |
EP2094234B1 (en) | Cosmetic formulation containing glucosyl glycerides and urea | |
DE102005049833A1 (en) | New alginate, in which carboxylic acid functional groups are partially esterified or etherified with an alkyl and/or aryl residue, useful for reducing the stickiness of cosmetic preparation | |
AU2015258134B2 (en) | Preparations having an outer gel phase and an inner particulate phase comprising stabilized oxidation-and/or UV-sensitive active ingredients | |
WO2009115165A2 (en) | Cooling preparations for contact with human skin and/or mucous membranes, containing (1r,2s,5r)-2-isopropyl-5-methyl-n-(2-(pyridin-2-yl)ethyl-cyclohexane carboxamide and/or (1r,2s,5r)-n-(4-(cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide | |
DE102014208440B4 (en) | Formulations with an outer gel phase and an inner particulate phase containing stabilized oxidation- and / or UV-sensitive agents | |
EP2942047B1 (en) | Cosmetic product | |
DE102014208436B4 (en) | Pearl-shaped cosmetic dosage forms | |
EP2942046B1 (en) | Compositions having an outer gel phase and an inner particulate phase, containing stabilised oxidation and/or UV-sensitive active agents | |
DE10307016B4 (en) | Cosmetic and / or dermatological preparation with liponamide, methods of solubilization and their use | |
ES2834960T3 (en) | Cosmetic product | |
DE102005026005A1 (en) | Cosmetic preparations containing a special aniseed extract and certain emulsifiers | |
DE102014208438A1 (en) | Pearl-shaped cosmetic dosage forms | |
EP3586816A1 (en) | Cosmetic product comprising a cosmetic or dermatological product containing visible beads suspended in a transparent, liquid or gel carrier, wherein the beads encapsulate a cosmetic or dermatological active ingredient which create an unpleasant odour | |
DE102014208441A1 (en) | Formulations with an outer gel phase and an inner particulate phase containing stabilized oxidation- and / or UV-sensitive agents | |
DE202014003725U1 (en) | Cosmetic product | |
DE202014003724U1 (en) | Preparations having an outer gel phase and an inner particulate phase containing stabilized oxidation- and / or UV-sensitive agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FEY, SVEN; MOEBIUS, JANNE AND BOELKE, DANA |
|
FGA | Letters patent sealed or granted (standard patent) |